ALK and non-small cell lung carcinoma: Though it has been shown that clinically these drugs are inferior to ALK TKIs as first-line therapy in patients with NSCLC harboring the ALK rearrangement, we find that there may be utility in considering these drugs after initial therapeutic resistance to ALK TKIs occurs, with many opportunities for collateral sensitivity (Fig. 4).